Patient-reported outcomes (PRO) in patients (pts) with BRCA1/2-altered metastatic castration-resistant prostate cancer (mCRPC) receiving niraparib (NIRA) with abiraterone acetate and prednisone (AAP): Results from MAGNITUDE study

被引：0
|
作者：
Rathkopf, Dana E.
Roubaud, Guilhem
Chi, Kim N.
Efstathiou, Eleni
Attard, Gerhardt
Olmos, David
Small, Eric J.
Saad, Marniza
Castro, Elena
Kim, Won
Wu, Daphne
Bertzos, Kristi
Dibaj, Shiva
Zhang, Jenny
Francis, Peter St. John
Smith, Matthew Raymond
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Inst Bergonie, Dept Med Oncol, Bordeaux, France
[3] Univ British Columbia, Vancouver, BC, Canada
[4] Houston Methodist Hosp, Dept Med Oncol, Houston, TX USA
[5] UCL, London, England
[6] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre, Madrid, Spain
[7] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[8] Univ Malaya, Fac Med, Dept Clin Oncol, Kuala Lumpur, Malaysia
[9] Univ Hosp Virgen de la Victoria HUVV, Malaga, Spain
[10] Janssen R&D US, Los Angeles, CA USA
[11] Janssen Res & Dev LLC, Los Angeles, CA USA
[12] Janssen Global Commercial Strategy Org, Horsham, PA USA
[13] Janssen Res & Dev LLC, San Diego, CA USA
[14] Johnson&Johnson, Spring House, PA USA
[15] Janssen Res & Dev LLC, Raritan, NJ USA
[16] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[17] Harvard Med Sch, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.4_suppl.105
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：105 / 105
页数：1
相关论文
共 50 条
  • [31] New drug approval: Fixed dose association of niraparib and abiraterone acetate in metastatic castration resistant prostate cancer with BRCA1/2 mutation
    Bischoff, Herve
    Barthelemy, Philippe
    BULLETIN DU CANCER, 2023, 110 (06) : 602 - 604
  • [32] Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy.
    Posadas, Edwin M.
    Chi, Kim N.
    De Wit, Ronald
    De Jonge, Maja J.
    Attard, Gerhardt
    Friedlander, Terence W.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [33] Clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (ABI) stratified by prognosis
    Aviles, C. M.
    Azad, A. A.
    Todenhoefer, T.
    Eigl, B. J.
    Kollmannsberger, C.
    Murray, N.
    Chi, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S486 - S487
  • [34] THE IMPACT OF ABIRATERONE ACETATE (AA) THERAPY ON PATIENT-REPORTED PAIN AND FUNCTIONAL STATUS IN CHEMOTHERAPY-NAIVE PATIENTS WITH PROGRESSIVE, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Basch, E.
    Ryan, C. J.
    Kheoh, T.
    Fizazi, K.
    Logothetis, C. J.
    Rathkopf, D. E.
    Smith, M. R.
    Mainwaring, P. N.
    Hao, Y.
    Griffin, T.
    Li, S.
    Meyers, M.
    Molina, A.
    Cleeland, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 295 - 295
  • [35] Phase 1/2 trial of cabazitaxel with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone acetate: Phase 2 results.
    Mateo, Joaquin
    Fizazi, Karim
    Pezaro, Carmel Jo
    Loriot, Yohann
    Mehra, Niven
    Albiges, Laurence
    Bianchini, Diletta
    Varga, Andrea
    Ryan, Charles J.
    Petrylak, Daniel Peter
    Shen, Liji
    Zhang, Jenny
    Attard, Gerhardt
    De Bono, Johann Sebastian
    Massard, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [36] Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer
    Tagawa, Scott T.
    Posadas, Edwin M.
    Bruce, Justine
    Lim, Emerson A.
    Petrylak, Daniel P.
    Peng, Weimin
    Kheoh, Thian
    Maul, Scott
    Smit, Johan W.
    Gonzalez, Martha D.
    De Porre, Peter
    NamPhuong Tran
    Nanus, David M.
    EUROPEAN UROLOGY, 2016, 70 (05) : 718 - 721
  • [37] A RETROSPECTIVE STUDY ON PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PRESCRIBED ABIRATERONE ACETATE plus PREDNISONE PRIOR TO CHEMOTHERAPY IN SWEDEN, NORWAY AND DENMARK
    Leval, A.
    Thelander, Flordal E.
    Kjolhede, H.
    Kongsted, P.
    Lindberg, H.
    Heinrich, D.
    Andren, O.
    VALUE IN HEALTH, 2018, 21 : S21 - S21
  • [38] Health-related quality of life (HRQoL) patient-reported outcomes (PROs) and survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)
    David, Lorente
    Lozano, Rebeca
    de Velasco, Guillermo
    Romero-Laorden, Nuria
    Castro, Elena
    Rodrigo-Aliaga, Miguel
    Sanchez, Angel L.
    Di Capua, Carlos
    Sanchez-Hernandez, Alfredo
    Olmos, David
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [39] Blood biomarkers and association with clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC): prespecified longitudinal analysis from the ACIS study of apalutamide (APA) or placebo combined with abiraterone acetate plus prednisone (AAP).
    Efstathiou, Eleni
    Attard, Gerhardt
    Lucas, Justin
    Thomas, Shibu
    Gormley, Michael
    Aguilar-Bonavides, Clemente
    Flaig, Thomas W.
    Franke, Fabio
    Goodman, Oscar B.
    Oudard, Stephane
    Pieczonka, Christopher Michael
    Li, Susan
    Dibaj, Shiva
    Brookman-May, Sabine D.
    Yeruva, Kesav
    McCarthy, Sharon Anne
    Steuber, Thomas
    Suzuki, Hiroyoshi
    Rathkopf, Dana E.
    Saad, Fred
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [40] Final results from ACIS, a randomized, placebo (PBO)-controlled double-blind phase 3 study of apalutamide (APA) and abiraterone acetate plus prednisone (AAP) versus AAP in patients (pts) with chemo-naive metastatic castration-resistant prostate cancer (mCRPC).
    Rathkopf, Dana E.
    Efstathiou, Eleni
    Attard, Gerhardt
    Flaig, Thomas W.
    Franke, Fabio Andre
    Goodman, Oscar B.
    Oudard, Stephane
    Steuber, Thomas
    Suzuki, Hiroyoshi
    Wu, Daphne
    Yeruva, Kesav
    De Porre, Peter
    Brookman-May, Sabine Doris
    Li, Susan
    Li Jinhui
    Mundle, Suneel
    McCarthy, Sharon Anne
    Saad, Fred
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345